Other Events ·
Alterity Therapeutics announced that CEO David Stamler will participate in the virtual BTIG Biotechnology Conference…
PRNAFAlterity Therapeutics Ltd
Alterity Therapeutics announced that CEO David Stamler will participate in the virtual BTIG Biotechnology Conference 2026 on July 28-29, 2026, to conduct one-on-one investor meetings. The company is currently preparing to initiate a Phase 3 pivotal trial for its lead asset, ATH434, in Multiple System Atrophy (MSA). Alterity Therapeutics is a clinical-stage biotechnology company developing disease-modifying treatments for neurodegenerative diseases.